ISL MEDISOURCE, LLC – Trademark Portfolio

Entity Type: 16

ISL MEDISOURCE, LLC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ULTIZYME and ULTITOUCH. The owner is based in CONWAY, AR.

17B NABCO AVENUE

CONWAY, AR 72033

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ULTITOUCH
ULTITOUCH
Registered 2005
ULTIZYME
ULTIZYME
Registered 2004

Trademark Classifications

ISL MEDISOURCE, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does ISL MEDISOURCE, LLC have?

ISL MEDISOURCE, LLC has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does ISL MEDISOURCE, LLC file in?

ISL MEDISOURCE, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are ISL MEDISOURCE, LLC's most well-known trademarks?

ISL MEDISOURCE, LLC's registered trademark portfolio includes well-known marks such as ULTIZYME and ULTITOUCH. These are among 2 currently registered trademarks in the portfolio.

What is ISL MEDISOURCE, LLC's trademark registration success rate?

ISL MEDISOURCE, LLC has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.